Yucel, SerapKadioglu, HuseyinGural, ZeynepAkgun, ZuleyhaSaglam, Esra Kaytan2023-02-212023-02-212021-01-0110.4103/jcrt.JCRT_774_16https://hdl.handle.net/11443/2104http://dx.doi.org/10.4103/jcrt.JCRT_774_16Aims: To evaluate the results of chemoradiation with intensity-modulated radiation therapy (IMRT) or volumetric-modulated arc therapy (VMAT) for the treatment of anal canal cancer patients at three institutions that had advanced devices. Materials and Methods: A retrospective analysis was performed for patients treated with 5-fluorouracil and mitomycin-based chemotherapy and IMRT or VMAT for anal cancer from 2011 to 2013. Complete response (CR) rates, colostomy-free survival (CFS), disease-free survival (DFS), overall survival (OS), and toxicities were investigated. Toxicities were evaluated with the Common Terminology Criteria for Adverse Events, Version 3.0. Results: Fifteen patients were included in the analysis. The majority of patients had T2 (53.3\%) and N0 (40\%) disease according to the staging system that was developed by the American Joint Committee on Cancer. CR was observed in 14 patients (93\%), and the median follow-up was 26 months (13-42 months). The 3-year CFS, DFS, and OS were 86\%, 86\%, and 88\%, respectively. Acute Grade 3 toxicities were observed as 6\% of hematological, 26\% of gastrointestinal, and 26\% of dermatological. Conclusion: Early results confirm that IMRT or VMAT for anal cancer treatment reduces acute toxicities while maintaining high control rates.Anal cancerchemoradiotherapyintensity-modulated radiation therapyvolumetric-modulated arc therapyArticleWOS:000631942900009